Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Katerina A. Politi"'
Autor:
Margarida Barroso, Milan G. Chheda, Hans Clevers, Elena Elez, Salma Kaochar, Scott E. Kopetz, Xiao-Nan Li, Funda Meric-Bernstam, Clifford A. Meyer, Haiwei Mou, Kristen M. Naegle, Martin F. Pera, Zinaida Perova, Katerina A. Politi, Benjamin J. Raphael, Paul Robson, Rosalie C. Sears, Josep Tabernero, David A. Tuveson, Alana L. Welm, Bryan E. Welm, Christopher D. Willey, Konstantin Salnikow, Jeffrey H. Chuang, Xiling Shen
Publikováno v:
Cancer Cell. Cell Press
3D patient tumor avatars (3D-PTAs) hold promise for next-generation precision medicine. Here, we describe the benefits and challenges of 3D-PTA technologies and necessary future steps to realize their potential for clinical decision making. 3D-PTAs r
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7b65654a1b4acc56953d02023b85344d
https://pubmed.ncbi.nlm.nih.gov/36270276
https://pubmed.ncbi.nlm.nih.gov/36270276
Autor:
Fernando J. de Miguel, Wesley L. Cai, Mary Ann Melnick, Camila Robles-Oteiza, Anna Wurtz, Maria I. Toki, David L. Rimm, Robert Homer, Don X. Nguyen, Katerina A. Politi
Publikováno v:
Cancer Research. 82:1094-1094
Targeted therapies have transformed the clinical management of many types of tumors, including EGFR-mutant lung adenocarcinomas. Although these treatments are highly beneficial for patient survival, acquired resistance almost inevitably occurs limiti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2c2f2151d610a304ab386abd8990c276
https://doi.org/10.1158/1538-7445.am2022-1094
https://doi.org/10.1158/1538-7445.am2022-1094
Autor:
Michael J Grant, Jacqueline V Aredo, Jacqueline Starrett, Anna Wurtz, Zofia Piotrowska, Andrew Piper-Vallillo, Helena Alexandra Yu, Christina Falcon, Tejas Patil, Christina Nguyen, Charu Aggarwal, Dylan G. Scholes, Fangyong Li, Manali Phadke, Joel W. Neal, Zenta Walther, Katerina A. Politi, Sarah B. Goldberg
Publikováno v:
Journal of Clinical Oncology. 40:e21112-e21112
e21112 Background: EGFR exon 19 deletions (del19) are largely considered to have uniform sensitivity to EGFR tyrosine kinase inhibitors (TKIs). Approximately 70% of del19 tumors harbor the most common deletion, E756_A750del; however, many “uncommon
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6485ab73a7e11189cfcc9b1a7b9f3374
https://doi.org/10.1200/jco.2022.40.16_suppl.e21112
https://doi.org/10.1200/jco.2022.40.16_suppl.e21112
Autor:
William Pao, Vincent A Miller, Katerina A Politi, Gregory J Riely, Romel Somwar, Maureen F Zakowski, Mark G Kris, Harold Varmus
Publikováno v:
PLoS Medicine, Vol 2, Iss 3, p e73 (2005)
Lung adenocarcinomas from patients who respond to the tyrosine kinase inhibitors gefitinib (Iressa) or erlotinib (Tarceva) usually harbor somatic gain-of-function mutations in exons encoding the kinase domain of the epidermal growth factor receptor (
Externí odkaz:
https://doaj.org/article/0ce48cfc553b458cbb75aa784a66d060
Autor:
David C, Christiani, William, Pao, James C, DeMartini, R Ilona, Linnoila, Alvin M, Malkinson, Amir, Onn, Katerina A, Politi, Michael, Sharp, Kwok-Kin, Wong, Kwok, Kim
Publikováno v:
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 1
Human bronchioloalveolar carcinoma (BAC) is a disease with an evolving definition. "Pure" BAC, characterized by a bronchioloalveolar growth pattern and no evidence of stromal, vascular, or pleural invasion, represents only 2 to 6% of non-small cell l
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::31f44ca5e969fa5f64d332a2855883d6
https://pubmed.ncbi.nlm.nih.gov/17409996
https://pubmed.ncbi.nlm.nih.gov/17409996